目的 观察厄贝沙坦联合瑞舒伐他汀对冠心病大鼠心肌及主动脉干s分泌型磷脂酶A2-V(sPLA2-V)的影响.方法 将50只Wistar大鼠随机分为正常组、模型组、厄贝沙坦组、瑞舒伐他汀组及厄贝沙坦联合瑞舒伐他汀组(联合用药组).采用喂饲高脂饲料和腹腔注射脑垂体后叶素方法制备冠心病大鼠模型.免疫组化及Western blot测定各组大鼠心肌及主动脉干sPLA2-Ⅴ的表达.结果 模型组大鼠心肌及主动脉干sPLA2-Ⅴ的表达显著高于其他各组(P ＜ 0.05),联合用药组sPLA2-Ⅴ的表达均显著低于厄贝沙坦组及瑞舒伐他汀组(P ＜ 0.05).结论 厄贝沙坦联合瑞舒伐他汀可能通过抑制心肌及主动脉干sPLA2-Ⅴ的表达起到抗动脉粥样硬化治疗冠心病作用,可作为心血管疾病高危人群的一级预防.%Objective To observe the effect on sPLA2-V expression of myocardium and aorta stem in coronary heart disease rats treated by Irbesartan combined with Rosiivastatin. Methods 50 Wistar rats were randomly divided into normal group, model group, Irbesartan group, Rosuvastatin group, Irbesartan combined with Rosuvastatin group (combined group). Except normal group, the other groups were given high fat foods and intraperitoneal injection of pituitrin method in preparation for coronary heart disease rat model. The expression of sPLA2- V in myocardium and aorta stem was determined by immunohistochemistry and western blot. Results The sPLA2- V expression in myocardium and aorta stem of model group was significantly higher than that of the other groups (P < 0.05). But in combined group, it was significantly lower than that of Irbesartan group and Rosuvastatin group (P < 0.05). Conclusion Irbesartan combined with Rosuvastatin has a anti-atherosclerosis therapy of coronary heart disease by inhibiting the expression of sPLA2- V in myocardium and aorta stem. It can be as a primary prevention for cardiovascular disease risk populations.
展开▼
